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We have read with great interest, but also with some
concern, the paper by Tarvasmäki et al., recently published
in Critical Care [1]. In this observational study, adrenaline
was independently associated with mortality in cardio-
genic shock (CS). The data presented are the odds ratio
(OR) of a multivariable propensity score-adjusted analysis,
where patients that used adrenaline had an adjusted OR
of 3.0 (95 % confidence interval 1.3–7.2) for 90-day
mortality in comparison with patients who had not
received adrenaline.
The main concern with the article is precisely the
choice of the OR as its measure of effect. The misleading
use of OR as an approximation of the relative risk (RR)
when the outcome of interest is very frequent (which is
certainly the case in this study, where the mortality
incidence was around 40 %) is a long recognized problem
and alternative methods for analysis, such as the Poisson
regression with robust variance, have been suggested as
appropriate approaches to estimate the RR for more than
a decade [2]. Since the authors did not present the
RR, one could use a suggested well-known formula
[3] to estimate the RR from a given OR and outcome
incidence: RR = OR/(1 − Incidence + (Incidence × OR)).
Applying this equation, the RR for 90-day mortality
would be 1.67 (1.16–2.07).
Although this number still shows a statistically signifi-
cant increase in mortality, one must remember that this
information comes from an observational study. The
GRADE working group proposal for rating the quality of
evidence for interventions ranks the conclusions from
observational studies as low quality evidence [4]. This
quality of evidence can be rated up if a large magnitude
of effect is present. However, the suggestion in the
GRADE guidelines is that this rating up should be done
when the RR as at least equal to 2, which was not the
case in this study [5]. In conclusion, the evidence
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suggesting an increased mortality risk associated with
adrenaline use in CS is low quality (at best, since one
could rate it down to very low quality if we consider that
there is imprecision in the estimate) and, therefore,
an adequately designed and powered clinical trial is
imperative to provide a reliable answer to this question.
Authors’ response to “Increased mortality with the use of adrenaline in shock: the evidence
is still limited”
Tuukka Tarvasmäki, Reijo Sund, Johan Lassus, Alexandre Mebazaa and Veli-Pekka Harjola
We thank Ribeiro and Restelatto for their comments on
our article about assessing the concurrent use of vaso-
active medications in cardiogenic shock [1]. They raise
two potential issues regarding our main finding, the as-
sociation between adrenaline use and 90-day mortality:
the use of the odds ratio (OR) instead of relative risk
(RR) and that the evidence is from an observational
study. While we agree that the OR might not always
accurately describe the RR, logistic regression analysis is a
gold standard statistical technique for binary responses, so
it was an obvious choice also in our study. Moreover, after
conversion from ORs, both the univariate and adjusted
multivariable RR for adrenaline use were over 2 (2.3 and
2.2, respectively).
As we were curious about the association between
adrenaline use and increased mortality, we performed
and reported further analyses using additional propensity
score adjustments in the subgroup of vasopressor-
treated patients as described in our article. The effect
size diminished a bit but remained statistically significant
(OR 3.0, 95 % confidence interval 1.3–7.2, p = 0.01). We
also reported analyses using propensity score matching,
Kaplan–Meier curves and log-rank tests, as well as an
adjusted Cox regression model and the association was
statistically significant regardless of the analysis tech-
nique. As suggested by Ribeiro and Restelatto, we per-
formed an additional analysis using Poisson regression
with robust variance: for adrenaline use in a multivari-
able model with propensity score adjustment within the
subgroup of vasopressor-treated patients, the RR for
90-day mortality was 1.5 (95 % confidence interval 1.1–2.1,
p = 0.017), i.e., still a statistically significant association.
So, the main finding is supported by several sensitivity
analyses and we can be confident that there is a clearly
statistically significant association between adrenaline
use and 90-day mortality in our data. Albeit being a
result from an observational study, we argue that this is
still a clinically significant finding, especially considering
the very high frequency of (poor) outcome also empha-
sized by Ribeiro and Restelatto. This warrants attention
because it raises justified questions about the safety of this
treatment. And we fully agree, as we conclude in our
article, that there is a need for randomized controlled trial
to confirm this detected association.
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